Download PDF
Neuropediatrics 2016; 47(02): 112-114
DOI: 10.1055/s-0035-1565272
Short Communication
Georg Thieme Verlag KG Stuttgart · New York

Age-Dependent Seroprevalence of JCV Antibody in Children

Eva Maria Hennes
1   Olgahospital – Pediatrics, Kriegsbergstraße, Stuttgart 70174, Germany
,
Barbara Kornek
2   Medical University Vienna, Neurology, Vienna, Austria
,
Peter Huppke
3   Medical University Göttingen, Pediatric Neurology, Göttingen, Germany
,
Markus Reindl
4   Medical University of Innsbruck, Neurology, Innsbruck, Austria
,
Kevin Rostasy
5   Vestische Kinderklinik Datteln, Pediatric Neurology, Datteln, Germany
,
Thomas Berger
6   Medical University of Innsbruck, Neurology, Innsbruck, Austria
› Author Affiliations
Further Information

Publication History

14 May 2015

01 September 2015

Publication Date:
19 October 2015 (online)

    Permissions and Reprints

Abstract

Progressive multifocal leukoencephalopathy (PML) is an opportunistic central nervous system infection, caused by the John Cunningham virus (JCV). PML may occur during treatment with immunosuppressive agents or monoclonal antibodies such as natalizumab. The JCV seroprevalence increases with age with a seropositivity of 60% in the adult human population. In this study, we analyzed sera from 109 pediatric multiple sclerosis (MS) patients (mean age 14 years) as well as sera from 162 patients with a wide range of suspected neurologic disorders (mean age 6.3 years). Our results showed a considerably lower seroprevalence for JCV in our pediatric cohort with 33.3% and equal distribution in both subgroups, compared with reported seropositivity in adult population. This could result in a lower risk for drug-induced PML in pediatric patients compared with adult patients and can influence the indication for natalizumab therapy in pediatric MS patients.

Keywords

JCV - multiple sclerosis - progressive multifocal leukoencephalopathy
 

  • References

  • 1 Ferenczy MW, Marshall LJ, Nelson CD , et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 2012; 25 (3) 471-506
    CrossrefPubMedGoogle Scholar
  • 2 Iacobaeus E, Ryschkewitsch C, Gravell M , et al. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. Mult Scler 2009; 15 (1) 28-35
    CrossrefPubMedGoogle Scholar
  • 3 White MK, Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy—revisited. J Infect Dis 2011; 203 (5) 578-586
    CrossrefPubMedGoogle Scholar
  • 4 Warnke C, Dehmel T, Posevitz-Fejfár A , et al. Anti-JC-virus antibody prevalence in a German MS cohort. Mult Scler 2012; 18 (7) 1054-1055
    CrossrefPubMedGoogle Scholar
  • 5 Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog 2009; 5 (3) e1000363
    CrossrefPubMedGoogle Scholar
  • 6 Gorelik L, Lerner M, Bixler S , et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68 (3) 295-303
    CrossrefPubMedGoogle Scholar
  • 7 Knowles WA, Pipkin P, Andrews N , et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003; 71 (1) 115-123
    CrossrefPubMedGoogle Scholar
  • 8 Polo C, Pérez JL, Mielnichuck A, Fedele CG, Niubò J, Tenorio A. Prevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children. Clin Microbiol Infect 2004; 10 (7) 640-644
    CrossrefPubMedGoogle Scholar
  • 9 Viscidi RP, Rollison DE, Sondak VK , et al. Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus. Clin Vaccine Immunol 2011; 18 (10) 1737-1743
    CrossrefPubMedGoogle Scholar
  • 10 Huppke P, Hummel H, Ellenberger D , et al. JC virus antibody status in a pediatric multiple sclerosis cohort: prevalence, conversion rate and influence on disease severity. Mult Scler 2015; 21 (4) 382-387
    CrossrefPubMedGoogle Scholar